Hints and tips:
...Takeda, Nycomed and Nordic Capital, the largest investor with 41 per cent of the shares, all refused to comment....
...Deutsche Bank advised Takeda and Goldman Sachs and Credit Suisse worked for Nycomed....
...This wave of refinancings and several large disposals to cash-rich strategic buyers – such as the $13.7bn sale of Swiss pharmaceutical group Nycomed to Japanese rival Takeda – funnelled back a lot of money...
...Takeda Pharmaceutical is finalising an offer for Nycomed, the specialist privately held Swiss-headquartered generic drugs and consumer healthcare group with a large emerging market presence....
...Nycomed, a privately held business with a presence in Russia and Brazil, will expand into China with the purchase of 51.3 per cent of Guangdong Techpool Bio-Pharma for $214m....
...But deals in Europe have included the second-largest cross-border takeover by a Japanese company, with Takeda Pharmaceutical’s $13.7bn agreement to buy Nycomed of Switzerland....
...The US drugmaker beat UCB of Belgium and Nycomed of Switzerland to buy the division....
...Nycomed is 41 per cent owned by Nordic Capital, the Swedish buy-out group....
...Nycomed, the privately owned Swiss company, is in the second round of the auction process, while US drug company Abbott Laboratories was said to be mulling an offer for Solvay’s TriCor cholesterol treatment...
International Edition